Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939715 | 0.91 | CHRM1 (0.75) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL4635787 | 0.90 | CHRM1 (0.73) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4635917 | 0.89 | CHRM1 (0.64) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4932146 | 0.88 | CHRM1 (0.82) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4636035 | 0.88 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4637024 | 0.86 | CHRM1 (0.81) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4636107 | 0.86 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4939010 | 0.81 | CHRM1 (0.71) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4939063 | 0.80 | CHRM1 (0.75) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4934302 | 0.79 | CHRM1 (0.67) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CHRM2 2/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.